🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "huge turning point" in the battle against superbug strains of the bacteria, according to scientists.

A Global Health Concern

Cases of gonorrhoea are on the rise globally, with estimates suggesting more than 82 million new cases each year. Notably increased rates are seen in Africa and countries within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while figures across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary step in the reality of growing infection rates, the spread of superbugs and the highly restricted available drugs presently on offer.”

Health officials are particularly alarmed about the increase in drug-resistant strains. The global health body has classified it as a "high-priority threat". A tracking program revealed that resistance to primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Treatment Options Secure Clearance

Zoliflodacin, alternatively called Nuzolvence, was cleared by the American regulatory agency in recent days for combating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Researchers hope that targeted use of this new drug will help slow the development of resistance.

Another new antibiotic, created by the drugmaker GSK, gained clearance in close succession. This medication, which is additionally indicated for urinary tract infections, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin was the result of a new, not-for-profit approach for medication research. The non-profit organisation GARDP partnered with the pharmaceutical company its industry partner to see it through.

“This approval marks a significant shift in the management of multidrug-resistant gonorrhoea, which until now has been evolving faster than antibiotic development.”

Research Study Outcomes and Global Access

Based on findings detailed in a prominent scientific publication, zoliflodacin cured the vast majority of genital gonorrhoea infections. This establishes an comparable level with the current standard treatment, which uses two antibiotics. The trial enrolled nearly 1,000 participants from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, GARDP has the authority to license and sell the drug in numerous low-income and middle-income countries.

Medical professionals directly involved have voiced hope. The availability of a single-dose, oral treatment of this kind is seen as a "critical tool" for gonorrhoea control. This is considered essential to lessen the impact of the disease for individuals and to halt the transmission of untreatable gonorrhoea around the world.